Celgene's AML drug clears late-stage test

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 16, 2019 at 9:32 AM.

  1. #1 cafead, Sep 16, 2019 at 9:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,013
    Likes Received:
    3
    via Celgene is gearing up for regulatory submissions, after a pivotal acute myeloid leukemia (AML) study showed its drug helped patients live longer.

    The drugmaker — which is in the process of being swallowed by Bristol-Myers Squibb $BMY — tested its experimental drug, CC-486, in newly-diagnosed patients with AML who fully or partially benefited from chemotherapy.

    article source
     
    Quote

Reply to Thread